Updated:
Laboratorios Farmaceuticos Rovi, S.A.
Rovi was founded in 1946 by Juan López-Belmonte Lozano as a pharmaceutical laboratory in Madrid, Spain.
Laboratorios Farmaceuticos Rovi, S.A.
Rovi was founded in 1946 by Juan López-Belmonte Lozano as a pharmaceutical laboratory in Madrid, Spain. The company went public on the Madrid Stock Exchange in 1952 and remains controlled by the López-Belmonte family. The current president and CEO, Juan López-Belmonte López, is the third generation to run the firm. Wealth originates from pharmaceutical manufacturing and sales across Spain and Latin America, though the family has not disclosed a separate office structure (per public record). Rovi operates as a fully integrated pharmaceutical company involved in research, development, manufacturing, and commercialization of drugs. Its portfolio includes the top-selling low-molecular-weight heparin Bemiparin (Hibor) and the Roxane brand of immediate-release oral dosage forms. Since 2021, Rovi has served as the fill-finish manufacturing partner for Moderna's COVID-19 vaccine in Spain, a contract that accounted for roughly 40% of 2023 revenue (per Rovi annual report, 2023). The company invests in specialty injectable drugs, biosimilars, and drug-device combination products. Geographically, Rovi sells across 50+ countries, with primary markets in Europe, Latin America, and the Middle East. The company employs approximately 2,500 people, including a dedicated R&D site in Granada. Rovi maintains production facilities in Madrid and Granada (Spain) and a joint venture factory in Lima, Peru for the Latin American market. In May 2024, Rovi announced the acquisition of a proprietary pipeline of peptide-based drugs from a European biotech for €75M (per Rovi press release, May 2024). The López-Belmonte family owns roughly 55% of the company (per Rovi 2024 annual report), giving them majority control without a separate family-office vehicle publicly documented. Rovi's dual identity as a publicly traded company and a family-controlled business is its core structural differentiator. The López-Belmonte family has maintained both operational management and board control since founding, avoiding a standard single-family-office model. The company's strong cash flow from contract manufacturing supports direct investment in its own pipeline, rather than relying on external venture funding. Succession is legally structured through family ownership of shares, with the CEO role passing to the third generation.
General information
Firm type
other
Year founded
1946
AUM
Undisclosed
Location
Region
Europe
Country
Spain
City
Madrid
Corporate office
Madrid, Spain
Principals
Juan López-Belmonte López
President and CEO
Sector focus
Frequently asked questions
Who controls Rovi today?
The López-Belmonte family, led by third-generation president and CEO Juan López-Belmonte López, controls roughly 55% of the company's shares (per Rovi 2024 annual report). The family does not operate a separate single-family office; control is exercised directly through the board and management, making Rovi a rare European public company still under founding-family operational control.
How does Rovi make money beyond its own drug sales?
Rovi operates a contract development and manufacturing organization (CDMO) segment focused on sterile injectables and drug-device combinations. Its largest CDMO contract has been the fill-finish production of Moderna's COVID-19 vaccine, which contributed roughly 40% of 2023 revenue (per Rovi annual report, 2023). The CDMO business also services other pharmaceutical firms, providing a recurring revenue stream alongside proprietary product sales.
What is Rovi's relationship with the ADR ticker?
The ADR (American Depositary Receipt) ticker LFRVV trades on the OTC market, representing shares of the underlying Madrid-listed company. This vehicle provides US investors access to the stock without trading directly on the Madrid Stock Exchange. The ADR does not represent a separate legal entity or investment fund; it is a sponsored program.
Does Rovi operate a family office or investment arm outside the listed company?
No publicly documented family office exists for the López-Belmonte family. The family appears to conduct all significant investment activities through Rovi itself, including its R&D pipeline and corporate acquisition strategy. This is consistent with a family that maintains concentrated ownership in a single public operating company rather than diversifying into separate investment vehicles.
What is Rovi's pipeline focus beyond COVID-19 vaccines?
Rovi invests in low-molecular-weight heparin (Bemiparin), specialty injectable generics, biosimilars, and drug-device combination products. In May 2024, the company acquired a European biotech's peptide-based drug pipeline for €75M (per Rovi press release, May 2024), signaling expansion beyond anticoagulants into areas like metabolic and endocrine therapies.
Does the family have a succession plan in place?
The family has completed one generational transition: Juan López-Belmonte López (third generation) took over as CEO. The company's public filings acknowledge family control, but specific succession provisions beyond the current CEO are not detailed in public documents. The family's majority shareholding provides structural control, with governance governed by standard Spanish corporate law.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: